About Us Our BioBank Platform Technology Our Drug Programmes News Contact us Press Releases INVESTORS NEWS 2021 2020 2019 2018 2017 2016 Pre 2016 11th November 2021 Synairgen completes Phase III recruitment 20th October 2021 SNG001 progresses to Phase 3 of ACTIV-2 trial 13th October 2021 Synairgen appoints Gareth Walters, Ph.D. as Chief Regulatory Officer 30th September 2021 Interim results for the six months ended 30 June 2021 30th September 2021 Non-Executive Director Appointment 21st September 2021 Notice of Interim Results 18th June 2021 Result of AGM 25th May 2021 Posting of Annual Report and Notice of AGM 24th May 2021 Results of in vitro studies 12th May 2021 Preliminary statement of results for the year ended 31 December 2020 30th April 2021 Home Cohort data of SG016 Phase II trial 15th February 2021 Dosing commenced in US ACTIV-2 trial 25th January 2021 Inclusion in US ACTIV-2 trial 20th January 2021 Home trial recruitment completed 13th January 2021 First Patient Dosing in Phase III SG018 Trial Synairgen plc Registered in England and Wales No. 5233429 Registered office Mailpoint 810, Level F, South Block, Southampton General Hospital, Tremona Road, Southampton, SO16 6YD, UK